Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy and Safety of GW685698X (Fluticasone Furoate) in Persistent Asthma
NCT00603278Phase 2Completed
- Sponsor
- GSK
- Start
- Dec 2007
- Primary completion
- Nov 2008
- Modality
- Orthosteric Ligands
- Countries
- 13
01
Overview
Phase 2, randomised, double-blind trial of fluticasone in asthma (3 arms), sponsored by GSK. Primary endpoint: Mean Change From Baseline in Trough (Evening Pre-dose and Pre- Rescue Bronchodilator) FEV1 at 8 weeks. Started Dec 2007; status: completed.
02
Drugs
fluticasone
03
Conditions
asthma
Beyond the preview
Go deeper on NCT00603278.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00603278.